[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoadjuvant-chemoradiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoadjuvant-chemoradiotherapy":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100572700",false,"NCT06736678","Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients","Efficacy of Oral Immunonutrition Therapy in Reducing Acute Toxicity After Neoadjuvant Chemoradiotherapy Among Pancreatic Cancer Patients: a Prospective, Single-arm Clinical Trial","Inclusion Criteria:\n\n* 1\\. Pathologically confirmed pancreatic ductal epithelial malignant tumors;\n* 2\\. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;\n* 3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;\n* 4\\. Age 18 years and older;\n* 5\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 6\\. Expected survival time more than 3 months;\n* 7\\. History of antineoplastic therapy;\n\nExclusion Criteria:\n\n* 1\\. Known allergy or intolerance to any component of investigational Oral Immunonutrition;\n* 2\\. History of Oral Immunonutrition use within one month prior to enrollment;\n* 3\\. Tumor compresses the major duodenal papilla, and \u002For appeared jaundice, acute pancreatitis;\n* 4\\. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;\n* 5\\. Liver, kidney and blood coagulation function failure;\n* 6\\. Patients with hemopathy;\n* 7\\. Patients with active infections;\n* 8\\. Patients with other primary tumor;\n* 9\\. Patients with other medical diseases that seriously affected nutritional status;\n* 10.Subjects deemed by the investigator have other factors that may be ineligible for enrollment;","ALL","18 Years",{"count":18,"type":19},98,"ESTIMATED","INTERVENTIONAL",[22],"NA","A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.",[25,26,27],"Pancreatic Cancer","Neoadjuvant Chemoradiotherapy","Immunonutrition","RECRUITING","2024-12-12",{"date":31,"type":32},"2024-12-17","ACTUAL",{"date":34,"type":32},"2024-08-26",{"date":36,"type":19},"2025-09-30",{"name":38,"class":39},"Sun Yat-sen University","OTHER",2,""]